Skip to main content
Top
Published in: BMC Public Health 1/2022

Open Access 01-12-2022 | Public Health | Research

Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China

Authors: Wenjun Liu, Tianyi Zhuang, Ruyi Xia, Zhuoru Zou, Lei Zhang, Mingwang Shen, Guihua Zhuang

Published in: BMC Public Health | Issue 1/2022

Login to get access

Abstract

Background

The World Health Organization (WHO) requires reduction in the prevalence of hepatitis B virus (HBV) surface antigen (HBsAg) in children to 0.1% by 2030, a key indicator for eliminating viral hepatitis as a major public health threat. Whether and how China can achieve this target remains unknown, although great achievements have been made. We aimed to predict the decline of HBsAg prevalence in China and identify key developments needed to achieve the target.

Methods

An age- and time-dependent dynamic compartmental model was constructed based on the natural history of HBV infection and the national history and current status of hepatitis B control. The model was run from 2006 to 2040 to predict the decline of HBsAg prevalence under three scenarios including maintaining current interventions (status quo), status quo + peripartum antiviral prophylaxis (PAP, recommended by WHO in 2020), and scaling up current interventions + PAP.

Results

Under the status quo, HBsAg prevalence would decrease steadily in all age groups, but the WHO’s target of 0.1% prevalence in children aged < 5 years would not be achieved until 2037. The results are robust according to sensitivity analyses. Under the status quo + PAP, the HBsAg prevalence of children aged < 5 years would significantly decrease with the introduction of PAP, and the higher the successful interruption coverage is achieved by PAP, the more significant the decline. However, even if the successful interruption coverage reaches 90% by 2030, the 0.1% prevalence target would not be met until 2031. Under the scaling up current interventions + PAP, combined with scale-up of current interventions, the WHO’s 0.1% target would be achieved on time or one year in advance if PAP is introduced and the successful interruption coverage is scaled up to 80% or 90% by 2030, respectively.

Conclusions

It is difficult for China to achieve the WHO’s target of 0.1% HBsAg prevalence in children by 2030 by maintaining current interventions. PAP may play an important role to shorten the time to achieve the target. A comprehensive scale-up of available interventions including PAP will ensure that China achieves the target on schedule.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chinese Center for Disease Control and Prevention. Seroepidemiological investigation of HBV in Chinese population. Beijing: People’s Medical Publishing House; 2011 (Chinese). Chinese Center for Disease Control and Prevention. Seroepidemiological investigation of HBV in Chinese population. Beijing: People’s Medical Publishing House; 2011 (Chinese).
2.
go back to reference Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–7.CrossRef Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–7.CrossRef
3.
go back to reference Bureau of Disease Prevention and Control, National Health Commission, Chinese Center for Disease Control and Prevention. The national report of hepatitis B serosurvey among 1–29 years old population in China. Beijing: People’s Medical Publishing House; 2018. (Chinese). Bureau of Disease Prevention and Control, National Health Commission, Chinese Center for Disease Control and Prevention. The national report of hepatitis B serosurvey among 1–29 years old population in China. Beijing: People’s Medical Publishing House; 2018. (Chinese).
4.
go back to reference Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009;200(1):39–47.CrossRef Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009;200(1):39–47.CrossRef
5.
go back to reference Liang P, Zu J, Yin J, Li H, Gao L, Cui F, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992–2006: A mathematical model analysis. J Theor Biol. 2015;386:115–21.CrossRef Liang P, Zu J, Yin J, Li H, Gao L, Cui F, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992–2006: A mathematical model analysis. J Theor Biol. 2015;386:115–21.CrossRef
6.
go back to reference Romano L, Paladini S, Damme PV, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis. 2011;43(Suppl 1):S2-7.CrossRef Romano L, Paladini S, Damme PV, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis. 2011;43(Suppl 1):S2-7.CrossRef
7.
go back to reference Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease. China Bull World Health Organ. 2019;97(3):230–8.CrossRef Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease. China Bull World Health Organ. 2019;97(3):230–8.CrossRef
8.
go back to reference WHO. Global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization; 2016. WHO. Global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization; 2016.
9.
go back to reference WHO. Consolidated strategic information guidelines for viral hepatitis planning and tracking progress towards elimination. Geneva: World Health Organization; 2019. WHO. Consolidated strategic information guidelines for viral hepatitis planning and tracking progress towards elimination. Geneva: World Health Organization; 2019.
10.
go back to reference Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–408.CrossRef Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–408.CrossRef
11.
go back to reference WHO. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization; 2019. WHO. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization; 2019.
12.
go back to reference Cui J, Cao L, Zheng JS, Cao LS, Yuan P, Li L. Coverage analysis of national immunization program vaccines reported in China, 2013. Chin J Vacc Imm. 2015;21(3):289–94 (330 (Chinese)). Cui J, Cao L, Zheng JS, Cao LS, Yuan P, Li L. Coverage analysis of national immunization program vaccines reported in China, 2013. Chin J Vacc Imm. 2015;21(3):289–94 (330 (Chinese)).
13.
go back to reference Cui J, Cao L, Zheng JS, Cao LS, Duo MJ, Xiao QY. Reported coverage of vaccines in the national immunization program of China, 2015. Chin J vacc and imm. 2017;23(6):601–7 ((Chinese)). Cui J, Cao L, Zheng JS, Cao LS, Duo MJ, Xiao QY. Reported coverage of vaccines in the national immunization program of China, 2015. Chin J vacc and imm. 2017;23(6):601–7 ((Chinese)).
14.
go back to reference Zhang XS, Jiao YZ, Tang Y, Deng L, Zhang NJ, Li XB. Quality evaluation on routine immunization surveillance data in Gansu province in 2019. Chin Primary Health Care. 2020;34(10):87–9 (92 (Chinese)). Zhang XS, Jiao YZ, Tang Y, Deng L, Zhang NJ, Li XB. Quality evaluation on routine immunization surveillance data in Gansu province in 2019. Chin Primary Health Care. 2020;34(10):87–9 (92 (Chinese)).
15.
go back to reference Ye LX, Zhao XF, Fang T, Dong HJ, Ma R, Lin HB, et al. Coverage of hepatitis B vaccine and hepatitis B immunoglobulin administration rates among children born to hepatitis B surface antigen positive mothers during 2013–2018 in Ningbo city. Chin J Vacc Imm. 2020;26(1):82–7 (103 (Chinese)). Ye LX, Zhao XF, Fang T, Dong HJ, Ma R, Lin HB, et al. Coverage of hepatitis B vaccine and hepatitis B immunoglobulin administration rates among children born to hepatitis B surface antigen positive mothers during 2013–2018 in Ningbo city. Chin J Vacc Imm. 2020;26(1):82–7 (103 (Chinese)).
16.
go back to reference Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328–36.CrossRef Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328–36.CrossRef
17.
go back to reference Coates T, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23(3):392–403.CrossRef Coates T, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23(3):392–403.CrossRef
18.
go back to reference Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396–404.CrossRef Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396–404.CrossRef
19.
go back to reference WHO. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017;92(27):369–92. WHO. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017;92(27):369–92.
20.
go back to reference WHO. Prevention of mother-to-child transmission of hepatitis B virus guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020. WHO. Prevention of mother-to-child transmission of hepatitis B virus guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.
21.
go back to reference Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.CrossRef Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.CrossRef
22.
go back to reference Wang AL, Qiao YP, Wang LH, Fang LW, Wang F, Jin X, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ. 2015;93(1):52–6.CrossRef Wang AL, Qiao YP, Wang LH, Fang LW, Wang F, Jin X, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ. 2015;93(1):52–6.CrossRef
23.
go back to reference Society for Maternal-Fetal M, Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214(1):6–14.CrossRef Society for Maternal-Fetal M, Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214(1):6–14.CrossRef
24.
go back to reference Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol. 2019;17(10):1929-1936.e1.CrossRef Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol. 2019;17(10):1929-1936.e1.CrossRef
25.
go back to reference Xin X, Wang Y, Cheng J, Zhang Y, Peng Z, Xu J, et al. Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: A cross-sectional study. J Clin Virol. 2016;81:47–52.CrossRef Xin X, Wang Y, Cheng J, Zhang Y, Peng Z, Xu J, et al. Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: A cross-sectional study. J Clin Virol. 2016;81:47–52.CrossRef
26.
go back to reference Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582–92.CrossRef Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582–92.CrossRef
27.
go back to reference Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329–39.CrossRef Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329–39.CrossRef
28.
go back to reference Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43(3):556–62.CrossRef Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43(3):556–62.CrossRef
29.
go back to reference Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45(5):1187–92.CrossRef Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45(5):1187–92.CrossRef
30.
go back to reference de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3-25.PubMed de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3-25.PubMed
31.
32.
go back to reference Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22(2):157–63.PubMed Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22(2):157–63.PubMed
33.
go back to reference Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun. 2015;6:6588.CrossRef Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun. 2015;6:6588.CrossRef
34.
go back to reference Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319–33.CrossRef Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319–33.CrossRef
35.
go back to reference Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37(Suppl 1):33–9.CrossRef Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37(Suppl 1):33–9.CrossRef
Metadata
Title
Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
Authors
Wenjun Liu
Tianyi Zhuang
Ruyi Xia
Zhuoru Zou
Lei Zhang
Mingwang Shen
Guihua Zhuang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2022
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-022-13594-y

Other articles of this Issue 1/2022

BMC Public Health 1/2022 Go to the issue